Temozolomide may cause thrombocytopenia or neutropenia in 3–4% of glioblastoma
patients, respectively. However, pancytopenia is rarely reported. MGMT (O6-methylguanine …

Purpose Nearly 10% of patients with adult diffuse glioma develop clinically significant
myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions. This study …

Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma
multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair …

Glioblastoma multiforme is the most common primary central nervous system tumor, with an
incidence of 3.2 per 100,000 per year [1]. Patients with glioblastoma have a poor twoyear …

First-line therapy for patients with glioblastoma multiforme includes treatment with radiation
and temozolomide (TMZ), an oral DNA alkylating chemotherapy. Sensitivity of glioma cells to …

Background The use of temozolomide (TMZ) has improved the prognosis for glioblastoma
multiforme patients. However, TMZ resistance may be one of the main reasons why …

The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) is known to play
a role in sensitivity to temozolomide. Promoter hypermethylation of MGMT is commonly used …

This study aims to investigate the associations of O 6-methylguanine-DNA methyltransferase
(MGMT) genetic polymorphisms (Leu84Phe and Ile143Val) with temozolomide (TMZ) …

Background: O 6-methylguanine-DNA methyltransferase (MGMT) expression in
glioblastoma correlates with temozolomide resistance. Dose-intense temozolomide …

Background Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase)
DNA-repair gene by promoter methylation compromises DNA repair and has been …